NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)

Prior treatment

• Patient has already received \>2 cycles of 1L CPD
• Unable to swallow orally administered medication.

Other illness

• Known hypersensitivity to carboplatin, paclitaxel, durvalumab and/or olaparib or any of the excipients of the drug.

Other

• Pregnancy or breast-feeding.
• Current or planned participation in an interventional clinical trial.
• Current or planned systemic treatment of any tumor other than primary advanced or recurrent EC.
• Patient has pathologically documented sarcoma

• Women aged ≥ 18 years at the time of screening.
• Patient has pathologically documented:
• Primary advanced (FIGO III and IV) epithelial EC OR
• Recurrent disease that is unlikely to be cured and where the multidisciplinary tumor board decision is systemic therapy. Carcinosarcomas are allowed,
• Patient is intended or initiated to receive 1L CPD followed by maintenance therapy with durvalumab (dMMR cohort) or with durvalumab and olaparib (pMMR cohort) according to the SmPC of IMFINZI® and Lynparza®\* prior to enrollment. Recruitment of patients that already started and may have received up to 2 cycles of CPD is allowed but will be capped to 25% for each cohort of the study population.
• Patient is eligible for treatment with durvalumab and/or olaparib as specified in the IMFINZI® and Lynparza® SmPC. The prescription of the medicinal product is clearly separated from the decision to include the patient in the study.
• MMR-testing results of the patient's tumor are known.
• Patient is willing and able to complete PRO questionnaires.
• Patient can read and understand German, English, Arab, Russian or Turkish.
• Signed written informed consent.